• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors

    4/12/21 7:30:00 AM ET
    $AZPN
    $NTLA
    $SLDB
    EDP Services
    Technology
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $AZPN alert in real time by email

    CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Georgia Keresty, Ph.D., M.P.H., to the company's Board of Directors.  

    "Dr. Keresty's experience as a scientific and operational leader in our industry will be a great asset to Intellia as we continue to advance our research programs, expand our manufacturing capabilities and move towards delivering potentially curative therapies to patients globally," said Intellia President and Chief Executive Officer John Leonard, M.D. 

    Dr. Keresty brings more than 35 years of pharmaceutical industry experience to Intellia's board, including leading the transition of novel therapeutic programs from preclinical to clinical development, and process development to commercial manufacturing. During her career, she has held key global roles in pharmaceutical research and development, operations, manufacturing and distribution, quality, compliance and regulatory affairs. Dr. Keresty recently served as chief operating officer and global head, medical sciences and development operations for Takeda Research and Development, a division of Takeda Pharmaceuticals USA, Inc. Prior to joining Takeda, Dr. Keresty served in leadership roles at Johnson & Johnson, including as vice president and global head, pharmaceutical development and manufacturing science; at Bristol-Myers Squibb Co., as vice president, worldwide quality and compliance; and at Novartis Pharmaceuticals Corporation as manufacturing site head.

    In addition to Intellia's board, Dr. Keresty serves as a member of the board of directors of Aspen Technology, Inc., (NASDAQ:AZPN), an industrial asset optimization software company and Solid Biosciences, Inc., (NASDAQ:SLDB), a life science company. She is also a member of the board of directors of Commissioning Agents, Inc., a global engineering services firm, and the board of trustees for Clarkson University in Potsdam, New York. She previously served on the board of Janssen Alzheimer Immunotherapy and the board of trustees for the New Jersey Foundation for Aging, which is now called the NJ Advocates for Aging Well.

    Dr. Keresty earned B.Sc. degrees in Chemical Engineering from Clarkson University and Computer Science from Ramapo College, an M.S. in Information Systems from Pace University, an M.B.A. and Ph.D. in Operations Management from Rutgers Business School, and an M.P.H. in Global Health Leadership from the University of Southern California. 

    About Intellia Therapeutics 

    Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products. Learn more about Intellia and CRISPR/Cas9 at intelliatx.com. Follow us on Twitter @intelliatweets. 

    Forward-Looking Statements 



    This press release contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's ability to advance and expand the CRISPR/Cas9 technology to develop into human therapeutic products, as well as our CRISPR/Cas9 intellectual property portfolio; achieve stable or effective genome editing; the timing and potential achievement of milestones to advance our pipeline and grow as a company; and the anticipated contribution of the members of our board of directors and our executives to our operations and progress.

    Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for its product candidates; the risk that any one or more of Intellia's product candidates will not be successfully developed, manufactured and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; the risk that Intellia may not be able to meet or comply with applicable laws and regulations, including clinical, manufacturing and commercialization requirements; and the risk that Intellia's collaborations with Novartis Institutes for BioMedical Research, Inc. or Regeneron Pharmaceuticals, Inc. or its other ex vivo collaborations will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Intellia's most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission ("SEC"). All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

    Intellia Contacts:

    Investors:

    Lina Li

    Director

    Investor Relations

    +1-857-706-1612

    [email protected]

    Media:

    Julie Ferguson

    Interim Head of External Affairs & Communications

    +1-312-385-0098

    [email protected] 



    Primary Logo

    Get the next $AZPN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZPN
    $NTLA
    $SLDB

    CompanyDatePrice TargetRatingAnalyst
    Intellia Therapeutics Inc.
    $NTLA
    4/21/2025$21.00Peer Perform → Outperform
    Wolfe Research
    Intellia Therapeutics Inc.
    $NTLA
    3/5/2025$30.00Buy
    H.C. Wainwright
    Intellia Therapeutics Inc.
    $NTLA
    2/28/2025$45.00 → $13.00Overweight → Neutral
    Analyst
    Intellia Therapeutics Inc.
    $NTLA
    2/28/2025$9.00Neutral → Sell
    Goldman
    Aspen Technology Inc.
    $AZPN
    2/10/2025$265.00 → $315.00Hold → Buy
    Loop Capital
    Aspen Technology Inc.
    $AZPN
    2/5/2025$260.00 → $265.00Buy → Hold
    Loop Capital
    Intellia Therapeutics Inc.
    $NTLA
    1/27/2025$56.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    Solid Biosciences Inc.
    $SLDB
    1/8/2025$16.00Buy
    Truist
    More analyst ratings

    $AZPN
    $NTLA
    $SLDB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kahn Clare bought $9,924 worth of shares (1,860 units at $5.34), increasing direct ownership by 169% to 2,960 units (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      3/13/25 4:05:03 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Bain Capital Life Sciences Investors, Llc bought $4,030,000 worth of shares (1,000,000 units at $4.03) (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      2/21/25 5:48:02 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Perceptive Advisors Llc bought $20,150,000 worth of shares (5,000,000 units at $4.03) (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      2/21/25 4:17:42 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AZPN
    $NTLA
    $SLDB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

      CHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, at 2:00 pm ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 30 days on the Events page. Institutional investors interested in meeting with ma

      5/28/25 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

      Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline, including in patients who were previously progressing on patisiranContinue to observe generally favorable safety and tolerability data in the full Phase 1 cohort with no new drug-related adverse events within the follow-up periodEnrollment continues to progress well in MAGNITUDE-2, which is designed to measure clinical outcomes (including mNIS+7) and evaluate how a single dose of nex-z can lead to reduction in serum TTR, to potentially support a BLA submission by 2028 CAMBRIDG

      5/18/25 7:25:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

      - Duchenne (SGT-003): Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant anticipated in the second half of 2025 - - CPVT (SGT-501): FDA IND on track for submission first half of 2025 - - Cash: Company ended first quarter 2025 with $306.9 million in cash, cash equivalents, investments and available-for-sale securities; Solid has anticipated cash runway into the first half of 2027 - CHARLESTOWN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision, next gen

      5/15/25 4:06:47 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AZPN
    $NTLA
    $SLDB
    SEC Filings

    See more
    • Intellia Therapeutics Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure

      8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

      5/28/25 4:38:43 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Solid Biosciences Inc.

      EFFECT - Solid Biosciences Inc. (0001707502) (Filer)

      5/28/25 12:15:12 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

      5/19/25 6:21:08 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AZPN
    $NTLA
    $SLDB
    Financials

    Live finance-specific insights

    See more
    • Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

      On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002 in patients with HAE at EAACI Congress in June 2025Expect to present longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study of nex-z

      5/8/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available throug

      5/1/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

      Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics License Application in the second half of 2026 to support plans for U.S. launch in 2027Enrollment in the pivotal Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis (ATTR) with cardiomyopathy continues to track ahead of projections; more than 550 total patients expected to be enrolled by year endActively screening for the Phase 3 MAGNITUDE-2 trial for nex-z in hereditary ATTR amyloidosis with polyneuropathy; on track to dose first patient in 1Q25En

      2/27/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AZPN
    $NTLA
    $SLDB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bhanji Muna sold $2,252 worth of shares (265 units at $8.50), decreasing direct ownership by 1% to 19,203 units (SEC Form 4)

      4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

      5/1/25 4:24:22 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Smith Ian F converted options into 4,574 shares, increasing direct ownership by 4% to 117,546 units (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      4/8/25 4:05:03 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CVP, Chief Accounting Officer Stagno Christopher disposed of 3,711 shares and returned 2,103 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Aspen Technology, Inc. (0001897982) (Issuer)

      3/13/25 4:31:53 PM ET
      $AZPN
      EDP Services
      Technology

    $AZPN
    $NTLA
    $SLDB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

      SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 7:59:25 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Solid Biosciences Inc.

      SC 13G - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 12:02:53 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Solid Biosciences Inc.

      SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 8:56:19 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AZPN
    $NTLA
    $SLDB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Intellia Therapeutics upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Intellia Therapeutics from Peer Perform to Outperform and set a new price target of $21.00

      4/21/25 8:30:53 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • H.C. Wainwright initiated coverage on Intellia Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Intellia Therapeutics with a rating of Buy and set a new price target of $30.00

      3/5/25 7:39:47 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics downgraded by Analyst with a new price target

      Analyst downgraded Intellia Therapeutics from Overweight to Neutral and set a new price target of $13.00 from $45.00 previously

      2/28/25 7:27:33 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AZPN
    $NTLA
    $SLDB
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Albertsons Companies Set to Join S&P MidCap 400

      NEW YORK, March 4, 2025 /PRNewswire/ -- Albertsons Companies Inc. (NYSE:ACI) will replace Aspen Technology Inc. (NASD: AZPN) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, March 11. S&P 500 constituent Emerson Electric Co. (NYSE:EMR) is acquiring Aspen Technology in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date  Index Name         Action  Company Name  Ticker  GICS Sector  March 11, 2025   S&P MidCap 400   Addition   Albertsons Companies ACI   Consumer Staples   March 11, 2025   S&P MidCap 400   Del

      3/4/25 6:41:00 PM ET
      $ACI
      $AZPN
      $EMR
      $SPGI
      Food Chains
      Consumer Staples
      EDP Services
      Technology
    • Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

      Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR

      11/16/24 10:16:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care